Innoviva Accounts Receivables 2011-2026 | INVA

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Innoviva

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
35 M	20.4 M	14.5 M	9.4 M	-	-	-	-	-	-	-	-	199 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
35 M	199 K	15.9 M

Quarterly Accounts Receivables Innoviva

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
30.2 M	20.9 M	16.7 M	20.4 M	30.5 M	26.8 M	14.1 M	14.5 M	10.8 M	15.3 M	15.5 M	9.4 M	6.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3 K	199 K	199 K	199 K	199 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
30.5 M	3 K	12.9 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
I-Mab IMAB	130 M	-	-	$ 866 M	China
Autolus Therapeutics plc AUTL	24 M	$ 1.34	-3.6 %	$ 357 M	Britain
Acorda Therapeutics ACOR	17.3 M	-	-24.86 %	$ 820 K	USA
DBV Technologies S.A. DBVT	2.23 M	$ 20.13	-1.13 %	$ 2.81 B	France
Advaxis ADXS	234 K	-	-9.65 %	$ 45.9 M	USA
Dyadic International DYAI	1.09 M	$ 0.87	-	$ 31.5 M	USA
Adverum Biotechnologies ADVM	886 K	-	-	$ 86.2 M	USA
Aytu BioScience AYTU	31.2 M	$ 2.57	-3.57 %	$ 16.1 M	USA
Equillium EQ	3.74 M	$ 2.04	1.24 %	$ 117 M	USA
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
Fate Therapeutics FATE	916 K	$ 1.13	-5.04 %	$ 134 M	USA
Fennec Pharmaceuticals FENC	23.2 M	$ 6.14	-4.36 %	$ 175 M	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
Amicus Therapeutics FOLD	115 M	$ 14.46	0.03 %	$ 4.46 B	USA
Fulcrum Therapeutics FULC	1.07 M	$ 7.55	-3.58 %	$ 478 K	USA
Gilead Sciences GILD	4.91 B	$ 138.19	-1.38 %	$ 172 B	USA
Coherus BioSciences CHRS	17.8 M	$ 1.61	-3.59 %	$ 189 M	USA
Galmed Pharmaceuticals Ltd. GLMD	812 K	$ 0.54	4.26 %	$ 503 K	Israel
Genmab A/S GMAB	34 M	$ 27.01	-2.67 %	$ 17.2 B	Danmark
Alnylam Pharmaceuticals ALNY	778 M	$ 314.44	-4.81 %	$ 41.2 B	USA
Gossamer Bio GOSS	12.2 M	$ 0.32	-7.11 %	$ 73.1 M	USA
Alpine Immune Sciences ALPN	392 K	-	-	$ 2.17 B	USA
GT Biopharma GTBP	40 K	$ 0.42	-6.49 %	$ 2.32 M	USA
Halozyme Therapeutics HALO	426 M	$ 63.51	0.68 %	$ 7.61 B	USA